Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Nusinersen:

Nusinersen for the treatment of spinal muscular atrophy. Chiriboga CA et al. Expert Rev Neurother. (2017)

Nusinersen: First Global Approval. Hoy SM et al. Drugs. (2017)

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. Finkel RS et al. N Engl J Med. (2017)

Search results

Items: 1 to 20 of 189

1.

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis.

Aslan N, Yildizdas D, Coban Y, Horoz OO, Mert GG, Ozcan N.

Indian J Pediatr. 2019 Sep 13. doi: 10.1007/s12098-019-03069-1. [Epub ahead of print] No abstract available.

PMID:
31520312
2.
3.

Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM.

Adv Ther. 2019 Sep 11. doi: 10.1007/s12325-019-01088-0. [Epub ahead of print] No abstract available.

PMID:
31512141
4.

Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.

Hoot NR.

Pediatrics. 2019 Sep 10. pii: e20190226. doi: 10.1542/peds.2019-0226. [Epub ahead of print] No abstract available.

PMID:
31506303
5.

Combination therapy with nusinersen and AVXS-101 in SMA type 1.

Lee BH, Collins E, Lewis L, Guntrum D, Eichinger K, Voter K, Abdel-Hamid HZ, Ciafaloni E.

Neurology. 2019 Sep 5. pii: 10.1212/WNL.0000000000008207. doi: 10.1212/WNL.0000000000008207. [Epub ahead of print] No abstract available.

PMID:
31488615
6.

[The incorporation of nusinersen by the Brazilian Unified National Health System: critical thoughts on the institutionalization of health technology assessment in Brazil].

Caetano R, Hauegen RC, Osorio-de-Castro CGS.

Cad Saude Publica. 2019 Aug 29;35(8):e00099619. doi: 10.1590/0102-311X00099619. Portuguese.

7.
8.
9.

Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.

LoMauro A, Mastella C, Alberti K, Masson R, Aliverti A, Baranello G.

Am J Respir Crit Care Med. 2019 Aug 21. doi: 10.1164/rccm.201906-1175LE. [Epub ahead of print] No abstract available.

PMID:
31433957
10.

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.

Darras BT, Farrar MA, Mercuri E, Finkel RS, Foster R, Hughes SG, Bhan I, Farwell W, Gheuens S.

CNS Drugs. 2019 Aug 16. doi: 10.1007/s40263-019-00656-w. [Epub ahead of print]

PMID:
31420846
11.

Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.

Meylemans A, De Bleecker J.

Acta Neurol Belg. 2019 Aug 6. doi: 10.1007/s13760-019-01199-z. [Epub ahead of print] Review.

PMID:
31388901
12.

Zolgensma - one-time gene therapy for spinal muscular atrophy.

[No authors listed]

Med Lett Drugs Ther. 2019 Jul 29;61(1577):113-114. No abstract available.

PMID:
31381549
13.

Spinal Muscular Atrophy: Past, Present, and Future.

Ross LF, Kwon JM.

Neoreviews. 2019 Aug;20(8):e437-e451. doi: 10.1542/neo.20-8-e437.

PMID:
31371553
14.

Routine Cerebrospinal Fluid Cytology Reveals Unique Inclusions in Macrophages During Treatment With Nusinersen.

Gingele S, Hümmert MW, Alvermann S, Jendretzky KF, Bönig L, Brieskorn M, Schwenkenbecher P, Sühs KW, Müschen LH, Osmanovic A, Schreiber-Katz O, Stangel M, Petri S, Skripuletz T.

Front Neurol. 2019 Jul 11;10:735. doi: 10.3389/fneur.2019.00735. eCollection 2019.

15.

Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.

Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O.

J Med Econ. 2019 Aug 4:1-10. doi: 10.1080/13696998.2019.1646263. [Epub ahead of print]

PMID:
31322019
16.

Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.

Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, Darras BT, Muntoni F, Mercuri E, De Vivo DC, Bishop KM, Schneider E, Bennett CF, Foster R, Farwell W; CS2 and CS12 Study Groups.

Muscle Nerve. 2019 Oct;60(4):409-414. doi: 10.1002/mus.26633. Epub 2019 Jul 27.

PMID:
31298747
17.

The Complex Spine in Children with Spinal Muscular Atrophy: The Transforaminal Approach-A Transformative Technique.

Towbin R, Schaefer C, Kaye R, Abruzzo T, Aria DJ.

AJNR Am J Neuroradiol. 2019 Aug;40(8):1422-1426. doi: 10.3174/ajnr.A6131. Epub 2019 Jul 11.

PMID:
31296522
18.

Nusinersen helps restore walking ability in childhood spinal muscular atrophy.

Sugimoto M, Aiba K, Koyama N, Yokochi K, Nishio H.

Pediatr Int. 2019 Jul;61(7):728-729. doi: 10.1111/ped.13867. Epub 2019 Jul 9. No abstract available.

PMID:
31290219
19.

Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.

Bennett CF, Krainer AR, Cleveland DW.

Annu Rev Neurosci. 2019 Jul 8;42:385-406. doi: 10.1146/annurev-neuro-070918-050501.

PMID:
31283897
20.

NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.

Torres-Benito L, Schneider S, Rombo R, Ling KK, Grysko V, Upadhyay A, Kononenko NL, Rigo F, Bennett CF, Wirth B.

Am J Hum Genet. 2019 Jul 3;105(1):221-230. doi: 10.1016/j.ajhg.2019.05.008. Epub 2019 Jun 20.

PMID:
31230718

Supplemental Content

Loading ...
Support Center